CMRX has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
CMRX has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Chimerix's EPS without NRI for the three months ended in Sep. 2024 was $-0.26.
During the past 3 years, the average EPS without NRI Growth Rate was -9.90% per year. During the past 5 years, the average EPS without NRI Growth Rate was 7.10% per year. During the past 10 years, the average EPS without NRI Growth Rate was 13.10% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.
During the past 13 years, the highest 3-Year average EPS without NRI Growth Rate of Chimerix was 22.60% per year. The lowest was -91.50% per year. And the median was 9.40% per year.
For the Biotechnology subindustry, Chimerix's 3-Year EPS without NRI Growth Rate, along with its competitors' market caps and 3-Year EPS without NRI Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Chimerix's 3-Year EPS without NRI Growth Rate distribution charts can be found below:
* The bar in red indicates where Chimerix's 3-Year EPS without NRI Growth Rate falls into.
This is the 3-year average growth rate of EPS without NRI. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.
Chimerix (NAS:CMRX) 3-Year EPS without NRI Growth Rate Explanation
EPS without NRI is the amount of earnings without non-recurring items per outstanding share of the company's stock.
Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists Earnings per share without Non-Recurring Items, which better reflects the company's underlying performance.
Thank you for viewing the detailed overview of Chimerix's 3-Year EPS without NRI Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.
Allen S. Melemed | officer: Chief Medical Officer | C/O CHIMERIX, INC., 2505 MERIDIAN PARKWAY, SUITE 100, DURHAM NC 27713 |
David Jakeman | officer: Principal Accounting Officer | C/O CHIMERIX, INC.,, 2505 MERIDIAN PARKWAY, SUITE 100, DURHAM NC 27713 |
Michael Albert Alrutz | officer: Principal Executive Officer | 2530 MERIDIAN PARKWAY, 2ND FLOOR, DURHAM NC 27713 |
Michael T. Andriole | officer: Chief Business Officer | C/O ENDOCYTE, INC., 3000 KENT AVENUE, SUITE A1-100, WEST LAFAYETTE IN 47906 |
Fred A Middleton | director | 400 SOUTH EL CAMINO REAL STE 1200, SAN MATEO CA 94402-1708 |
Michael A. Sherman | director, officer: Chief Executive Officer | 3000 KENT AVE STE A1-100, WEST LAFAYETTE IN 47906 |
Martha J Demski | director | 7770 REGENTS ROAD SUITE 113-505, SAN DIEGO CA 92122 |
Robert J. Meyer | director | 2505 MERIDIAN PARKWAY, C/O CHIMERIX, INC, SUITE 100, DURHAM NC 27713 |
Cantex Pharmaceuticals, Inc. | 10 percent owner | 1792 BELL TOWER LANE, SUITE 222, WESTON FL 33326 |
Victoria Vakiener | director | C/O EPIZYME, INC., 400 TECHNOLOGY SQUARE, CAMBRIDGE MA 02139 |
Pratik S Multani | director | C/O FATE THERAPEUTICS, INC., 3535 GENERAL ATOMICS COURT, SUITE 200, SAN DIEGO CA 92121 |
William Garrett Nichols | officer: Chief Medical Officer | C/O CANDEL THERAPEUTICS, INC., 117 KENDRICK ST SUITE 450, NEEDHAM MA 02494 |
M Michelle Berrey | officer: Chief Medical Officer | 303A COLLEGE ROAD EAST, PRINCETON NJ 08450 |
Ernest Mario | director | 20 FAIRMOUNT AVENUE, P.O. BOX 445, CHATHAM NJ 07928 |
Ed Greissing | director | 2505 MERIDIAN PARKWAY, C/O CHIMERIX, INC, SUITE 100, DURHAM NC 27713 |
From GuruFocus
By Marketwired • 02-18-2025
By Marketwired • 12-30-2024
By Marketwired • 11-11-2024
By Marketwired • 11-01-2024
By Marketwired • 01-29-2025
By Marketwired • 12-09-2024
By GuruFocus Research • 03-01-2024
By Marketwired • 10-18-2024
By Marketwired • 08-06-2024
By Marketwired • 04-16-2024
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.